Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17556991 | 1.00 | MEN1 (0.56) | MEN1POLBGAAKMT2ASLC6A3 | |
| SCHEMBL5749571 | 0.86 | MEN1 (0.53) | MEN1POLBGAAKMT2ASLC6A3 | |
| SCHEMBL900460 | 0.84 | MEN1 (0.66) | MEN1POLBGAAKMT2ASLC6A3 | |
| SCHEMBL16068413 | 0.82 | MEN1 (0.51) | MEN1POLBGAAKMT2ASLC6A3 | |
| SCHEMBL3049400 | 0.79 | GAA (0.66) | MEN1POLBGAAKMT2ASLC6A3 | |
| SCHEMBL11289321 | 0.77 | MEN1 (0.46) | MEN1POLBGAAKMT2ASLC6A3 | |
| SCHEMBL23338337 | 0.76 | POLB (0.56) | MEN1POLBGAAKMT2ASLC6A3 | |
| SCHEMBL21409728 | 0.76 | MEN1 (0.56) | MEN1POLBGAAKMT2ASLC6A3 | |
| SCHEMBL25171587 | 0.76 | MEN1 (0.56) | MEN1POLBGAAKMT2ASLC6A3 | |
| SCHEMBL31109609 | 0.75 | MEN1 (0.56) | MEN1POLBGAAKMT2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828338-B2 | Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068482-A1 | CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS | NAAA, FAAH, FAAH2 | MEN1 1885/4885POLB 2990/4885GAA 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.